Allurion Technologies Revenue

In the year 2025, Allurion Technologies had annual revenue of $15.23M, down -52.57%. Allurion Technologies had revenue of $3.61M in the quarter ending December 31, 2025, a decrease of -35.38%.

Revenue

15.23M

Revenue Growth

-52.57%

P/S Ratio

0.57

Revenue / Employee

111.99K

Employees

137

Market Cap

8.72M

Revenue Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	15.23M	-16.88M	-52.57%
Dec 31, 2024	32.11M	-21.36M	-39.94%
Dec 31, 2023	53.47M	-10.74M	-16.73%
Dec 31, 2022	64.21M	25.97M	67.91%
Dec 31, 2021	38.24M	-	-

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name	Revenue
Biotricity	15.45M
QHSLab	2.69M
Kelyniam Global	2.67M
BioElectronics	1.61M
AI Maverick Intel	92.26K
ALR Technologies SG	25.54K
REMSleep Holdings	6.73K
Ludwig Enterprises	207.00

Revenue Rankings

Allurion Technologies News

20 days ago - Allurion Advances Plan to Regain Listing Compliance - Business Wire
21 days ago - Allurion Begins Training and On‑Boarding of U.S. Accounts, Marking Major Milestone in Expansion Strategy - Business Wire
26 days ago - NYSE to Commence Delisting Proceedings Against Allurion Technologies, Inc. (ALUR) - Business Wire
4 weeks ago - Allurion Intends to Appeal NYSE Notice of Delisting, Execute Plan to Regain Compliance, and Expects to Continue Trading on NYSE - Business Wire
5 weeks ago - Allurion Announces Exercise of Warrants for $3.0 Million in Gross Proceeds - Business Wire
5 weeks ago - Allurion Receives U.S. FDA Approval - Business Wire
2 months ago - Allurion Announces Partnership to Offer Combination Therapy with Mounjaro® (tirzepatide) at Discounted Prices - Business Wire
2 months ago - Allurion Announces Preliminary Fourth Quarter and Full-Year 2025 Results - Business Wire

More News